Who
Jonathan Zalevsky
Chief R&D Officer
Company insider
Files Form 4 as: Chief R&D Officer, Nektar Therapeutics.
In numbers
- Trades disclosed
- 70
- Buys
- 0
- Sells
- 36
- Bought
- $0
- Sold
- $5.8M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 1 Oct 2019
- Last trade
- 18 Aug 2026
- Last filed
- 20 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Aug 2026filed 20 Aug 2026 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Sold | $13K186 at $71.98 | filing |
| 18 Aug 2026filed 20 Aug 2026 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Sold | $13K186 at $71.98 | filing |
| 24 Jul 2026filed 24 Jul 2026 | NKTR Nektar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,500 at $0.00 | filing |
| 24 Jul 2026filed 24 Jul 2026 | NKTR Nektar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,500 at $0.00 | filing |
| 30 Jun 2026filed 2 Jul 2026 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Sold | $398K5,681 at $70.00 | filing |
| 30 Jun 2026filed 2 Jul 2026 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Sold | $398K5,681 at $70.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Sold | $336K5,538 at $60.71 | filing |
| 15 Jun 2026filed 17 Jun 2026 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Sold | $336K5,538 at $60.71 | filing |
| 19 May 2026filed 21 May 2026 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Sold | $13K199 at $65.51 | filing |
| 19 May 2026filed 21 May 2026 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Sold | $13K199 at $65.51 | filing |
| 18 Feb 2026filed 20 Feb 2026 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Sold | $13K180 at $73.00 | filing |
| 18 Feb 2026filed 20 Feb 2026 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Sold | $13K180 at $73.00 | filing |
| 20 Jan 2026filed 22 Jan 2026 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Sold | $138K3,867 at $35.67 | filing |
| 20 Jan 2026filed 22 Jan 2026 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Sold | $138K3,867 at $35.67 | filing |
| 22 Dec 2025filed 23 Dec 2025 | NKTR Nektar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 22 Dec 2025filed 23 Dec 2025 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Code A | —6,250 at $0.00 | filing |
| 25 Nov 2025filed 25 Nov 2025 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Sold | $63K1,157 at $54.28 | filing |
| 21 Nov 2025filed 25 Nov 2025 | NKTR Nektar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,766 at $0.00 | filing |
| 21 Nov 2025filed 25 Nov 2025 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Code A | —2,666 at $0.00 | filing |
| 4 Sep 2025filed 8 Sep 2025 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Sold | $26K793 at $32.43 | filing |
News
Nektar Therapeutics (NASDAQ:NKTR) Research Coverage Started at Leerink PartnersNKTR · tickerreport.com · 15 Oct 2026Nektar Therapeutics (NASDAQ:NKTR) Now Covered by Analysts at Leerink PartnersNKTR · themarketsdaily.com · 13 Oct 2026
0 headlines in the last 90 days name Jonathan Zalevsky; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.